Dr. Winer Discusses Immunotherapy in Gynecologic Malignancies

Ira Winer, MD, PhD
Published: Tuesday, Apr 03, 2018



Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Immunotherapy has started to show promise in gynecologic malignancies. Winer says that it is being utilized in clinical trials of recurrent disease and in upfront trials. Currently, there is no way to select patients for these trials, Winer explains

Winer says that in a study of mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies, the implications for immune therapy were investigated.
SELECTED
LANGUAGE


Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Immunotherapy has started to show promise in gynecologic malignancies. Winer says that it is being utilized in clinical trials of recurrent disease and in upfront trials. Currently, there is no way to select patients for these trials, Winer explains

Winer says that in a study of mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies, the implications for immune therapy were investigated.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x